MARKET

LLY

LLY

Lilly Eli & Co
NYSE
883.88
-2.11
-0.24%
After Hours: 885.46 +1.58 +0.18% 19:59 06/21 EDT
OPEN
885.66
PREV CLOSE
885.99
HIGH
891.97
LOW
879.80
VOLUME
3.45M
TURNOVER
0
52 WEEK HIGH
905.45
52 WEEK LOW
431.12
MARKET CAP
840.04B
P/E (TTM)
130.10
1D
5D
1M
3M
1Y
5Y
Bullish bets on top-performing stocks like Nvidia surged to a record high this week
MarketWatch · 8h ago
Takeda gets EU approval for Fruzaqla for colorectal cancer
Seeking Alpha · 11h ago
Lilly weight loss drug tirzepatide meets primary endpoint in sleep apnea study
Seeking Alpha · 11h ago
Eli Lilly Announces Results From SURMOUNT-OSA Phase 3 Trials Evaluating Tirzepatide For Moderate-To-Severe Obstructive Sleep Apnea In Adults With Obesity; Achieves All Primary And Key Secondary Endpoints, Including Up To 62.8% Reduction In Apnea-Hypopnea Index
In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8%. Lilly has submitted the drug to the U.S. Food and Drug Administration for the treatment of OSA and obesity. The drug has been shown to reduce the severity of the condition.
Benzinga · 11h ago
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events per hour) In a key secondary endpoint from two clinical studies, 43.0% and 51.5% of participants with OSA met the criteria for disease resolution. Lilly has submitted the drug to the U.S. Food and Drug Administration for the treatment of OSA and obesity.
PR Newswire · 11h ago
Eli Lilly seeks FDA’s OK to expand Zepbound’s uses to include sleep apnea 
MarketWatch · 11h ago
Noteworthy Friday Option Activity: LLY, GS, BX
NASDAQ · 12h ago
'House panel weighs new plan for Medicare coverage of Wegovy, cancer blood tests' - Stat News
Benzinga · 12h ago
More
About LLY
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.

Webull offers Eli Lilly And Co stock information, including NYSE: LLY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LLY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LLY stock methods without spending real money on the virtual paper trading platform.